Research
Adherence
High out-of-pocket costs for semaglutide create a socioeconomic barrier to access, resulting in significantly lower prescription rates among low-income individuals despite them having a higher prevalence of obesity.
If you are on a limited budget, the high out-of-pocket cost of semaglutide may prevent you from accessing it, even if you have obesity. This is a systemic issue where low-income individuals are undertreated. Advocacy for reimbursement or subsidies is needed to address this inequality.
GoodSupportsHIGH confidence
This suggests that economic concerns lead to a systematic undertreatment for obesity for low-income individuals, potentially exacerbating existing health inequalities.
Why this rating
Large population-based register study (N=4.5M) with robust statistical adjustment.
Source
Association between socioeconomic factors and semaglutide use for weight loss: a population-based cross-sectional study in Denmark
Rasmus Bo Hasselbalch et al. · The Lancet Regional Health - Europe · 2025
cross_sectional · n=4531146Cited 7×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →